Sparsentan

AstraZeneca’s (LSE/STO/NYSE: AZN) Alexion unit reported that ravulizumab (Ultomiris) met the proteinuria primary endpoint in a prespecified interim analysis of the Phase III I CAN trial in adults with immunoglobulin A nephropathy, adding a potential new indication to a drug already approved across four complement-mediated diseases. The I CAN trial (ALXN1210-IgAN-320) is a global, randomized, double-blind, placebo-controlled study enrolling approximately 510 adults with IgAN who are at risk of disease progression, randomized 1:1 to ravulizumab or placebo for 106 weeks across 28 countries. At the week-34 interim analysis, ravulizumab produced a statistically significant reduction in proteinuria measured by 24-hour urine protein-to-creatinine ratio (UPCR) compared with placebo. The company reported that the reduction was detectable as early as week 10. No specific effect sizes, p-values, or confidence intervals were disclosed in the announcement; full data are expected at a forthcoming medical meeting. The second primary endpoint — change from baseline in estimated glomerular filtration rate at week 106 — remains pending at the final analysis. Safety was described as consistent with the established Ultomiris profile, with no new concerns identified. The decision to pursue accelerated approval in key markets on the basis of proteinuria reduction reflects a regulatory strategy that has precedent in IgAN. The FDA granted accelerated approval to sparsentan (Filspari, Travere Therapeutics) in 2023 on the basis of proteinuria reduction, with confirmatory eGFR data required. Iptacopan (Fabhalta, Novartis), a factor B inhibitor targeting the alternative complement pathway, received FDA approval for IgAN in 2024, also using proteinuria as the primary basis. The I CAN trial results position ravulizumab as a terminal complement inhibitor entering a space where upstream and midstream complement blockade already have regulatory footholds. The mechanistic distinction matters for how the data will be interpreted. IgAN pathogenesis involves aberrant IgA1 glycosylation leading to immune complex deposition in the glomerular mesangium, which activates the complement cascade. Iptacopan acts at factor B in the alternative pathway, upstream of C5. Ravulizumab blocks C5 cleavage directly, preventing generation of both the anaphylatoxin C5a and the membrane attack complex C5b-9. Whether terminal inhibition at C5 offers a different or additive clinical profile compared with upstream blockade is a question the field has not yet resolved, and cross-trial comparisons are limited by differences in patient populations, background therapy, and endpoint definitions across studies. Ravulizumab is an engineered variant of eculizumab with modifications that extend its half-life, allowing every-eight-week intravenous dosing in adults rather than the fortnightly schedule required for eculizumab. That pharmacokinetic profile has been central to its commercial positioning across its approved indications — paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disorder. In IgAN, the dosing interval could be relevant for patient adherence, though the intravenous route itself remains a practical consideration relative to oral agents such as iptacopan or sparsentan. The IgAN treatment landscape has shifted substantially since 2021, when the field had few options beyond renin-angiotensin-aldosterone system blockade and corticosteroids. Budesonide (Tarpeyo/Kinpeygo, Calliditas Therapeutics) received accelerated FDA approval in 2021 targeting mucosal IgA production. Sparsentan, a dual endothelin and angiotensin receptor antagonist, followed in 2023. Iptacopan, the first complement-targeted oral therapy for IgAN, added another mechanistic layer. The entry of a terminal C5 inhibitor with an established safety record across multiple approved indications introduces a drug with a known tolerability profile into this evolving treatment algorithm, though its precise positioning — monotherapy, add-on, or use in specific complement-driven subpopulations — will depend on the full week-106 dataset and regulatory review. The absence of numerical efficacy data in the current disclosure limits clinical interpretation. Proteinuria reduction is an accepted surrogate in IgAN, but the magnitude of that reduction, and whether it is sustained, carries weight for both regulatory and clinical decision-making. The FDA’s accelerated approval pathway for IgAN has explicitly tied post-marketing requirements to longer-term kidney function outcomes, meaning the eGFR readout at week 106 will be the more consequential dataset for understanding whether ravulizumab modifies disease trajectory rather than simply attenuating a biomarker. AstraZeneca said it plans to file for accelerated approval in key markets while the trial continues toward its final analysis, with full results to be presented at an unspecified medical meeting. Your email address will not be published. Required fields are marked * Comment * Name * Email * Website

The path to blockbuster sales for Travere's Filspari will start with a gradual ramp into 2028, Evercore ISI analysts predict. With the path to blockbusterland now in sight, Travere Therapeutics is ready to hit the ground running after Monday’s landmark approval for Filspari in focal segmental glomerulosclerosis (FSGS). Filspari is the first approved product for rare kidney disease and is poised to reach an addressable FSGS patient population of over 30,000, the company said in a presentation following the approval. Given its experience with Filspari's 2023 green light for IgA nephrography (IgAN), Travere boasts an “execution-ready” commercial platform that can support “long-term, sustainable revenue growth,” it said. Together with the IgAN population that the drug already covers, Filspari now has the potential to reach over 100,000 patients, according to Travere. From a market watcher's perspective, Evercore ISI analysts have forecasted peak sales of $1.4 billion from Filspari’s newly granted FSGS indication, while sales tied to IgAN usage are on track to top out at $800 million, the analysts wrote in a recent note to clients. Travere, for its part, is eyeing an even higher target, estimating a potential peak sales opportunity of more than $3 billion for Filspari in the U.S.To get there, the company has outlined a detailed launch plan that includes a customized patient support program built around FSGS, a focus on patient and physician education, an over 100-person-wide field team and a payer access foundation that builds on Filspari’s IgAN positioning. With the green light, Travere is immediately making Filspari available in its new indication, which the company described as a perk of its “streamlined logistics.” Filspari’s new label stipulates its use to reduce proteinuria, or protein in the urine, in FSGS patients ages eight years old and older without nephrotic syndrome. The Evercore team noted that Filspari won a broad label encompassing multiple disease subtypes, aside from the “surprise” exclusion of patients with nephrotic syndrome, which is a kidney disorder hallmarked by a specific range of high proteinuria levels. Still, the analysts noted that the lack of a nephrotic-specific label only impacts some 15% of the real-world FSGS patient population. The label, as defined, can be attributed to Filspari, showing a greater reduction in proteinuria across the cohort of patients who didn’t have nephrotic syndrome in Travere’s Duplex trial, with a 39% reduction from baseline levels for those patients compared to the 22% seen in the overall study population, the company explained. Travere is moving quickly on its launch, given the “high urgency” to treat FSGS. With more than 75% of FSGS patients expected to progress to dialysis and around 75% of surveyed nephrologists calling the condition “extremely challenging” to manage, the company aims to capitalize on “awareness and desire” for the new product. Additionally, a significant crossover opportunity lies in the 80% prescriber overlap with healthcare providers who offer Filspari under its IgA nephrography indication, Travere noted.  In that flagship indication, Filspari has stood firm against IgAN competition from Novartis and currently holds the title of the “most commonly prescribed” FDA-approved med for IgAN to date, the company said. In 2025, full-year sales of Filspari grew 144% from 2024 to $322 million. In the near term, the Evercore analysts predict sales from Filspari’s new indication to ramp up from an anticipated $55 million in 2026 to $315 million in 2027, followed by an estimated $640 million in 2028.Travere navigated numerous hurdles on the trek toward Filspari's FSGS approval, which was delayed by three months after the FDA requested more information characterizing the drug’s clinical benefit. The phase 3 Duplex study missed its primary endpoint in 2023, prompting the creation of a new endpoint for FSGS clinical trials. Then, more recently, concerns about the FDA’s handling of rare disease drug approvals began to emerge, prompting concern about how Filspari would fare at the agency’s desk. Now, with the Filspari nod secured, the approval presents a “significant positive” for rare nephrology regulatory flexibility across the board, the Evercore analysts argued.